Recipharm AB and Moderna have signed a coronavirus vaccine manufacturing agreement.
Under the deal, Recipharm will produce Moderna’s vaccine at a facility in France, where the company has made investments and hired staff to meet the timeline goals for manufacturing. Vaccines manufactured at the site will be sold in markets outside the U.S.
Recipharm had already signed on to a fill-and-finish agreement with Moderna, whose COVID-19 vaccine has been approved for emergency use in the U.S. Pending further approvals outside of the U.S., the companies expect to start delivering vaccines from Recipharm’s facility in early 2021.
Read the Reuters report.
